Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Место блокаторов рецепторов ангиотензина в антигипертензивной терапии - Журнал Системные Гипертензии Том 11, №1
Место блокаторов рецепторов ангиотензина в антигипертензивной терапии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Артериальная гипертензия занимает основное место среди сердечно-сосудистых заболеваний, являющихся основной причиной смерти и нетрудоспособности. На сегодняшний день основной группой препаратов для лечения артериальной гипертензии остаются ингибиторы ангиотензинпревращающего фермента (ИАПФ). По данным многочисленных исследований, блокаторы рецепторов ангиотензина II по своей эффективности равны ИАПФ, однако они имеют лучший профиль переносимости и обеспечивают более высокую приверженность терапии. Одним из высокоэффективных, хорошо изученных препаратов со значительной доказательной базой является ирбесартан.
Ключевые слова: артериальная гипертензия, ренин-ангиотензиновая система, блокаторы рецепторов ангиотензина II, ирбесартан.
Key words: arterial hypertension, renin-angiotenzin system, angiotensin II receptor inhibitors, irbesartan.
Ключевые слова: артериальная гипертензия, ренин-ангиотензиновая система, блокаторы рецепторов ангиотензина II, ирбесартан.
________________________________________________
Key words: arterial hypertension, renin-angiotenzin system, angiotensin II receptor inhibitors, irbesartan.
Полный текст
Список литературы
1. Диагностика и лечение артериальной гипертензии. Кардиоваск. терапия и профилактика. 2008; 7 (6). Прил. 2.
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
3. Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension. J RAAS 2005; 6: 84–9.
4. Mimran A et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203–8.
5. Stumpe KO et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31–7.
6. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–42.
7. Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11: 445–53.
8. Fogari R et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511–8.
9. Neutel JM et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
10. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
12. Madrid AH, Marнn IM, Cervantes CE et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114–20.
13. Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613–5.
14. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
15. Neutel JM, Saunders E, Bakris GL et al. INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578–86.
16. Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797–805.
17. Hasford J et al. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569–75.
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
3. Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension. J RAAS 2005; 6: 84–9.
4. Mimran A et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203–8.
5. Stumpe KO et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31–7.
6. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–42.
7. Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11: 445–53.
8. Fogari R et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511–8.
9. Neutel JM et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
10. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
12. Madrid AH, Marнn IM, Cervantes CE et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114–20.
13. Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613–5.
14. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
15. Neutel JM, Saunders E, Bakris GL et al. INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578–86.
16. Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797–805.
17. Hasford J et al. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569–75.
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
3. Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension. J RAAS 2005; 6: 84–9.
4. Mimran A et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203–8.
5. Stumpe KO et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31–7.
6. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–42.
7. Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11: 445–53.
8. Fogari R et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511–8.
9. Neutel JM et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
10. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
12. Madrid AH, Marнn IM, Cervantes CE et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114–20.
13. Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613–5.
14. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
15. Neutel JM, Saunders E, Bakris GL et al. INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578–86.
16. Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797–805.
17. Hasford J et al. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569–75.
________________________________________________
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
3. Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension. J RAAS 2005; 6: 84–9.
4. Mimran A et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203–8.
5. Stumpe KO et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31–7.
6. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–42.
7. Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11: 445–53.
8. Fogari R et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511–8.
9. Neutel JM et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
10. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
12. Madrid AH, Marнn IM, Cervantes CE et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114–20.
13. Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613–5.
14. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
15. Neutel JM, Saunders E, Bakris GL et al. INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578–86.
16. Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797–805.
17. Hasford J et al. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569–75.
Авторы
А.И.Мартынов, И.В.Урлаева, Е.В.Акатова, О.П.Николин
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.